N30 Pharmaceuticals Garners $20,000,000 New Financing

  • Feed Type
  • Date
    11/20/2014
  • Company Name
    N30 Pharmaceuticals
  • Mailing Address
    3122 Sterling Circle Boulder, CO 80301 USA
  • Company Description
    N30 Pharmaceuticals, LLC is developing s-nitrosothiol therapies for important unmet needs in respiratory diseases. N30’s strategy focuses on administration of GSNO to the human airway, and development of small molecule inhibitors of GSNO reductase.
  • Website
    http://www.n30pharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $20,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds from the financing will primarily be used to advance the Company’s clinical trial program for N91115, a novel inhibitor S-nitrosoglutathione reluctase (GSNOR).
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy